Immunotherapy Archives

Startup Scout 22 Sep 2022

Cartography Biosciences unearths cancer immunotherapy targets

Despite its meteoric growth in the last twenty years, cancer immunotherapy research is hamstrung by a lack of viable drug targets. Cartography Biosciences is using a single-cell sequencing approach to meet this demand. Immuno-oncology as a field barely existed 20 years ago, but has rapidly grown into a thriving field of biotechnology research. This has […]

September 22, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 20 Sep 2022

Biopharma company Faron announces escalation data cancer treatment study

A clinical stage biopharma company has announced further dose escalation data from its phase 1/2 study looking at the safety and efficacy of a monotherapy in ten different hard-to-treat cancers. Latest progress from Faron Pharma’s MATINS (Macrophage Antibody To INhibit immune Suppression) study was focused on higher dose levels and frequencies to finalize the dose […]

September 20, 2022 - 4 minutesmins - By Liza Laws

glioblastoma oncolytic virus transgene 2

News and Trends 20 Sep 2022

Collaboration to develop new glioblastoma combination therapy nets €1.06M

Dutch biotech CimCure B.V., French biotech company Covalab, Amsterdam UMC (The Netherlands) and the University of Zurich (Switzerland), have received a €1.06M ($1.08M) grant from EUREKA Eurostars. With a total budget of €2.24M ($2.28M), including investments from the partners, the project aims to develop a new treatment against glioblastoma. CimCure is the lead coordinator of […]

September 20, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

Regen BioPharma files patent on new RNA/DNA-based approach to cancer immunotherapy

Regen BioPharma, Inc. has filed a provisional patent application with the USPTO entitled “Dual Checkpoint Inhibitor Aptamer Based Therapeutics.” The application covers novel compositions of matter capable of acting as conventional checkpoint inhibitor drugs while simultaneously silencing genes that regulate T cells and cancer cells such as NR2F6 and Survivin. The company says this platform […]

September 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Sep 2022

Global consortium looks to develop breakthrough RNA-based anti-cancer immunotherapy

The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, Israel, is to lead CanceRNA, a global consortium aiming to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses. While RNA-based therapies, namely mRNA vaccines, shone during the pandemic and saved millions of lives, they have yet to be successfully tested […]

September 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Sep 2022

Bugworks Research and Cytecare Cancer Hospitals to set up cancer research center

Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals are set to collaborate by setting up a dedicated research center. Suresh Ramu, co-founder & CEO, Cytecare Cancer Hospitals, said: “We are excited to partner with Bugworks Research, in this inspiring endeavor to discover novel treatments for different types of cancers. In 2016, […]

September 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

PDC*line Pharma presents results from phase I/II trial

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, has revealed the first results of its PDC-LUNG-101 phase I/II clinical trial with PDC*lung01. PDC*lung01 is the company’s therapeutic off-the shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). The preliminary data was presented at […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

Startup Scout 8 Sep 2022

Stratosvir is overcoming the viral immunotherapy delivery bottleneck

The U.K. startup Stratosvir is working to tackle the barriers to developing viral immunotherapies for cancer, including allowing intravenous delivery and making it possible to dose multiple times. Cancer immunotherapies have made great strides in the last decade, with some of the most important advances including CAR-T cell therapy and checkpoint inhibitors. One oncology field […]

September 8, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 8 Sep 2022

OncoBone signs deals with three partners to work on bone metastases

OncoBone Ventures has signed cooperation framework agreements with three partners. The company is a U.K. start up biotech looking to develop novel therapies for cancer patients with currently incurable bone metastases. The partners are: Okayama University in Japan, the University of Bradford in the U.K., and The Development Center for Biotechnology in Taiwan. The agreements […]

September 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Lytix Biopharma expanding advanced melanoma study to Europe

Lytix Biopharma, a Norwegian immuno-oncology company, has received regulatory approval from European authorities to start its ATLAS-IT-05 study in three European countries. ATLAS-IT-05 is a phase II combination study evaluating LTX-315 and pembrolizumab in patients with advanced melanoma. The study was initiated at MD Anderson Cancer Center in 2021 and is currently ongoing in the […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

CellOrigin Biotech (Hangzhou) Co., Ltd. and Qilu Pharmaceutical are to collaborate on strategic global collaborations to develop, manufacture and commercialize ‘off-the-shelf’ induced pluripotent stem cells (iPSC)-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer immunotherapy. Both companies will work on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials. “Innovation, and […]

September 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Aug 2022

Sanyou and KangaBio to collaborate on antibody drug development and innovation

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai KangaBio Co., Ltd. have reached an antibody drug licensing agreement. The subject of the agreement is a monoclonal antibody drug developed by Sanyou Biopharmaceuticals, which grants KangaBio an exclusive license to exploit the antibody for research, development, manufacturing and commercialization of immunotherapy products. Previously, KangaBio and Sanyou Biopharmaceuticals […]

August 29, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Cartography Biosciences unearths cancer immunotherapy targets

Biopharma company Faron announces escalation data cancer treatment study

Collaboration to develop new glioblastoma combination therapy nets €1.06M

Regen BioPharma files patent on new RNA/DNA-based approach to cancer immunotherapy

Global consortium looks to develop breakthrough RNA-based anti-cancer immunotherapy

Bugworks Research and Cytecare Cancer Hospitals to set up cancer research center

PDC*line Pharma presents results from phase I/II trial

Stratosvir is overcoming the viral immunotherapy delivery bottleneck

OncoBone signs deals with three partners to work on bone metastases

Lytix Biopharma expanding advanced melanoma study to Europe

CellOrigin Biotech and Qilu Pharmaceutical to develop CAR-iMAC cell therapy

Sanyou and KangaBio to collaborate on antibody drug development and innovation

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!